Regulatory T cells in solid tumor immunotherapy: effect, mechanism and clinical application

被引:0
|
作者
Yan Pan [1 ]
Hanqiong Zhou [2 ]
Zhenqiang Sun [1 ]
Yichen Zhu [2 ]
Zhe Zhang [3 ]
Jing Han [1 ]
Yang Liu [2 ]
Qiming Wang [1 ]
机构
[1] The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital,Department of Internal Medicine
[2] Henan Academy of Innovations in Medical Science,Institute of Cancer Research
[3] The First Affiliated Hospital of Zhengzhou University,Department of Colorectal Surgery
[4] The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital,Department of Radiation Oncology
关键词
D O I
10.1038/s41419-025-07544-w
中图分类号
学科分类号
摘要
The tumor-immune response is mobilized to suppress tumorigenesis, while the immune microenvironment and lymph node microenvironment are formed gradually during tumor progression. In fact, tumor surface antigens are not easily recognized by antigen-presenting cells. So it is hard for the immune system to kill the newly formed tumor cells effectively. In a normal immune environment, immune function is always suppressed to maintain the stability of the body, and regulatory T cells play an important role in maintaining immune suppression. However, during tumorigenesis, the suppression of regulatory T cell immune functions is more likely to contribute to tumor cell proliferation and migration leading directly to tumor progression. Therefore, focusing on the role of regulatory T cells in tumor immunity could improve tumor immunotherapy outcomes in the clinic. Regulatory T cells are more mature in hematologic system tumors than in solid tumors. However, there are continuing efforts to apply regulatory T cells for immunotherapy in solid tumors. This review describes the role of regulatory T cells in solid tumor immunotherapy from the perspective of prognosis, immune microenvironment remodeling, and current clinical applications. This summary could help us better understand the mechanisms of regulatory T cells in solid tumor immunotherapy and further expand their clinical application.
引用
收藏
相关论文
共 50 条
  • [41] Regulatory cells and the effect of cancer immunotherapy
    María Iglesias-Escudero
    Noelia Arias-González
    Eva Martínez-Cáceres
    Molecular Cancer, 22
  • [42] Immunotherapy of Cancer by Targeting Regulatory T cells
    Chen, Bo-Jin
    Zhao, Jing-Wen
    Zhang, Da-Hong
    Zheng, Ai-Hong
    Wu, Guo-Qing
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 104
  • [43] Functional regulatory T cells and allergen immunotherapy
    Rolland, Jennifer M.
    Gardner, Leanne M.
    O'Hehir, Robyn E.
    CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2010, 10 (06) : 559 - 566
  • [44] T regulatory cells, the evolution of targeted immunotherapy
    Nizar, S.
    Meyer, B.
    Galustian, C.
    Kumar, D.
    Dalgleish, A.
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2010, 1806 (01): : 7 - 17
  • [45] Regulatory T-cells in adoptive immunotherapy
    Hammer, MH
    Ang'ani, L
    Volk, HD
    Reinke, P
    AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 522 - 522
  • [46] Regulatory T cells as a target of cancer immunotherapy
    Nishikawa, Hiroyoshi
    ANNALS OF ONCOLOGY, 2016, 27
  • [47] Immunotherapy with regulatory T and B cells in periodontitis
    Zou, Juan
    Zeng, Zijun
    Xie, Wen
    Zeng, Zhimei
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 109
  • [48] Targeting regulatory T cells for immunotherapy in melanoma
    Lili Huang
    Yeye Guo
    Shujing Liu
    Huaishan Wang
    Jinjin Zhu
    Lingling Ou
    Xiaowei Xu
    Molecular Biomedicine, 2
  • [49] Regulatory T cells for immunotherapy of autoimmune diseases
    Pohar, J.
    O'Connor, R.
    Jouneau, L.
    Boudinot, P.
    Bunse, M.
    Uckert, W.
    Anderton, S. M.
    Liblau, R.
    Fillatreau, S.
    FEBS OPEN BIO, 2021, 11 : 38 - 39
  • [50] Effect and mechanism of circRNAs in tumor angiogenesis and clinical application
    Zhao, Luyang
    Guo, Yuying
    Guo, Yaxin
    Ji, Xiang
    Fan, Dandan
    Chen, Chen
    Yuan, Weitang
    Sun, Zhenqiang
    Ji, Zhenyu
    INTERNATIONAL JOURNAL OF CANCER, 2022, 150 (08) : 1223 - 1232